Daily Cosmetic Research Analysis
Three studies shape cosmetic and aesthetic dermatology today: a multi-laboratory validation of the KeraSkin Phototoxicity Assay supports its inclusion in OECD TG 498 and strengthens non-animal safety testing; a randomized split-face trial shows CE Ferulic serum reduces erythema and speeds recovery after nonablative fractional laser; and an investigator-blinded split-face non-inferiority trial finds adipose MSC-derived exosomes comparable to platelet-rich plasma for photoaged skin.
Summary
Three studies shape cosmetic and aesthetic dermatology today: a multi-laboratory validation of the KeraSkin Phototoxicity Assay supports its inclusion in OECD TG 498 and strengthens non-animal safety testing; a randomized split-face trial shows CE Ferulic serum reduces erythema and speeds recovery after nonablative fractional laser; and an investigator-blinded split-face non-inferiority trial finds adipose MSC-derived exosomes comparable to platelet-rich plasma for photoaged skin.
Research Themes
- Non-animal phototoxicity safety testing
- Post-laser cosmeceutical care and recovery
- Regenerative aesthetics: exosomes versus PRP
Selected Articles
1. KoCVAM-led validation of KeraSkin™ Phototoxicity Assay for inclusion in OECD TG 498.
A five-laboratory validation demonstrated that the KeraSkin reconstructed human epidermis phototoxicity assay achieves 97.6–100% predictive performance across reference and test chemical sets, meeting OECD TG 498 inclusion criteria. The assay enables robust, animal-free phototoxicity assessment for cosmetics and drugs.
Impact: Regulatory-grade validation of an animal-free phototoxicity assay directly supports safety assessment frameworks and reduces animal use while maintaining high predictive accuracy.
Clinical Implications: While not a clinical study, adoption of this assay can improve pre-market safety screening of topical agents, potentially reducing phototoxic adverse events in real-world use and streamlining regulatory submissions.
Key Findings
- Within-lab reproducibility was 91.7–100% and between-lab reproducibility was 100% for 12 reference chemicals across all labs.
- For 12 reference chemicals over 144 runs, sensitivity was 100% (72/72), specificity 98.6% (71/72), and accuracy 99.3% (143/144).
- For 32 test chemicals over 164 runs, sensitivity, specificity, and accuracy were each 97.6% (80/82, 80/82, 160/164).
- The assay fulfills requirements for inclusion as a ‘me-too’ method in OECD TG 498.
Methodological Strengths
- Multi-laboratory validation aligned with OECD Performance Standard No. 356
- High reproducibility and balanced sensitivity/specificity across reference and test sets
Limitations
- Designated as a ‘me-too’ method; innovation is incremental rather than first-in-class
- Validation focused on selected reference/test chemicals; generalizability to all photoreactive chemistries may require further testing
Future Directions: Broaden chemical applicability domains, compare head-to-head with existing OECD TG 498 methods, and develop decision trees integrating RhE phototoxicity data into risk assessment frameworks.
Phototoxicity (or photoirritation) is defined as an acute toxic response elicited by topically or systematically administered photoreactive chemicals after the exposure of the body to environmental light. Korean Center for the Validation of Alternative Methods (KoCVAM) developed and optimized an in vitro phototoxicity test method using KeraSkin™, a reconstructed human epidermis model (RhE), (KeraSkin™ Phototoxicity Assay) as a ‘me-too’ test method in a previous study. KeraSkin™ Phototoxicity Assay was added to the OECD Workplan for inclusion in OECD test guideline (TG) 498. This study, conducted based on OECD Performance Standard No. 356 by one lead laboratory and four participating laboratories, aimed to validate the relevance and reliability of the KeraSkin™ Phototoxicity Assay for regulatory application in the safety assessment of cosmetics and drugs. Based on the test results, the 12 reference chemicals showed 91.7% to 100% within-lab reproducibility and 100% between-lab reproducibility in all participating labs. Further, the predictive capacity for the 12 reference chemicals calculated based on the total number of runs (144) showed 100% sensitivity (72/72), 98.6% specificity (71/72), and 99.3% accuracy (143/144). Overall predictive capacity (32 test chemicals) calculated based on the total number of runs (164) showed 97.6% (80/82) sensitivity, 97.6% (80/82) specificity, and 97.6% (160/164) accuracy. KeraSkin™ Phototoxicity Assay thus fulfills the requirements to be included as a ‘me-too’ test method in OECD TG 498. KeraSkin™ Phototoxicity Assay is an in vitro phototoxicity test method based on human skin cells. It closely mimics the biochemical and physiological properties of the upper layer of the human skin (i.e., epidermis). Therefore, KeraSkin™ can be used to test chemicals for phototoxicity without using animals. This validation study of KeraSkin™ Phototoxicity Assay was conducted to evaluate its reliability and relevance using chemicals previously tested in animals. The results show that it fulfills the requirements to be included in OECD TG 498.
2. A Randomized, Investigator-Blinded, Split-Face, Controlled Trial Assessing Efficacy and Satisfaction of CE Ferulic Serum Following Nonablative Fractional Fraxel Laser Treatment for Photoaging Skin in Chinese Population.
In a randomized, investigator-blinded split-face trial (n=50), CE Ferulic serum applied immediately after nonablative fractional laser and for 7 days reduced erythema progression versus saline and improved erythema/melanin indices, hydration, satisfaction, and pain.
Impact: Provides randomized evidence to optimize post-laser cosmeceutical care, addressing common downtime symptoms and potentially improving patient experience and recovery.
Clinical Implications: Consider CE Ferulic as a post-NAFL regimen to attenuate erythema and support barrier function during the first week, with counseling on expected benefits and monitoring for irritation.
Key Findings
- Day-7 erythema score change was significantly lower on the CEF-treated side versus saline (0.04±0.40 vs 0.18±0.48; p=0.011).
- CEF improved erythema index, melanin index, and skin hydration compared with saline.
- Patient-reported outcomes favored CEF with higher overall satisfaction and less post-procedure pain.
Methodological Strengths
- Randomized, investigator-blinded, split-face controlled design
- Prospectively registered trial with objective biophysical endpoints (EI, MI, hydration)
Limitations
- Short follow-up limited to 7 days and single-population (predominantly young female) sample
- Single comparator (saline) without active control; single-center design
Future Directions: Evaluate longer-term outcomes, diverse skin phototypes, comparisons with other post-laser actives, and cost-effectiveness.
BACKGROUND: Following Nonablative fractional Fraxel laser (NAFL), a well-established treatment for skin rejuvenation, immediate post-procedural care is essential to address any potential complications and accelerate the healing process. AIMS: To evaluate the efficacy and patient satisfaction of a topical skincare regimen containing vitamin C, vitamin E, and ferulic acid-CE Ferulic serum (CEF) following NAFL treatment in the Chinese population. METHODS: In this randomized, investigator-blinded, split-face, controlled trial, patients with mild-to-moderate facial photodamage were randomized to receive CEF treatment on one side of the face and normal saline (NS) on the other side immediately after the NAFL procedure and daily during the 7-day follow-up. The primary endpoint was the change from baseline in erythema score on Day 7, with key secondary endpoints including changes from baseline in erythema index (EI), melanin index (MI), transepidermal water loss, skin hydration, skin sebum content, scabbing, edema, overall patient satisfaction, and post-procedure pain. RESULTS: In total, 50 patients (female 45/50) were enrolled in this study, with a mean age of 31.6 years. The mean change from baseline in erythema score was significantly lower on the CEF side than on the NS side on Day 7 post-NAFL treatment (0.04 ± 0.40 vs. 0.18 ± 0.48, p = 0.011). The CEF side also exhibited improved changes in EI, MI, and skin hydration, as well as higher overall satisfaction and less pain compared with the NS side. CONCLUSIONS: Applying CEF after NAFL treatment reduced erythema progression, maintained skin hydration, and promoted the healing process compared with NS. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2300069246.
3. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial.
In an investigator-blinded split-face non-inferiority trial with three RF microneedling sessions, topical adipose MSC-derived exosomes matched PRP in improving wrinkles, dyschromia, erythema, texture, and overall appearance, with histology confirming increased collagen I and glycosaminoglycans in both arms.
Impact: Offers first head-to-head comparative evidence positioning exosomes as a practical alternative to PRP for photoaged skin, with implications for patient preference and clinic workflow.
Clinical Implications: Topical exosomes can be considered for patients who prefer to avoid venipuncture or when PRP processing is impractical, potentially reducing visit time while achieving comparable outcomes.
Key Findings
- Exosomes and PRP produced equivalent improvements in wrinkles, dyschromia, erythema, texture, and overall appearance.
- Histology showed increased collagen I and glycosaminoglycans in both treatment arms without significant differences.
- Three sessions of RF microneedling were combined with split-face application (PRP vs topical exosomes) under investigator blinding.
Methodological Strengths
- Investigator-blinded split-face design controls for inter-individual variability
- Inclusion of histologic endpoints (collagen I and GAG) to corroborate clinical findings
Limitations
- Sample size and detailed quantitative outcomes not specified in the abstract
- Follow-up duration and trial registration status not reported; non-inferiority margins not described
Future Directions: Conduct larger, registered non-inferiority RCTs with predefined margins, longer follow-up, standardized exosome preparations, and safety monitoring.
BACKGROUND: Exosomes, an emerging treatment of interest to aesthetic dermatology, have therapeutic applications in skin rejuvenation, alopecia, atopic dermatitis, acne scarring, and wound healing. Platelet-rich plasma has been widely utilized for the same indications, among others. Currently, there are no trials comparing the two regenerative modalities in aesthetic dermatology. AIMS: To compare the efficacy and safety of adipose mesenchymal stem cell-derived (ASC) exosomes versus platelet-rich plasma for photoaged facial skin. METHODS: An investigator-blinded, split-face trial was conducted. Participants with mild to moderate photoaging underwent three radiofrequency microneedling treatments with PRP and topical exosomes each applied to one half of the face. RESULTS: Both exosomes and PRP equally improved wrinkling, dyschromia, erythema, texture, and overall skin appearance. Histological analysis confirmed increased collagen I and glycosaminoglycans, without significant differences between treatment arms. CONCLUSION: ASC exosomes are a promising PRP-alternative that may be attractive to needle-averse patients and can hasten the office visit duration, as phlebotomy and centrifugation are not required.